SAFETY, TOLERABILITY AND IMMUNOGENICITY OF MENINGOCOCCAL B RECOMBINANT VACCINE ADMINISTERED AS BOOSTER DOSE AT 12, 18 OR 24 MONTHS OF AGE IN TODDLERS (12-24 MONTHS) PRIMED WITH A THREE-DOSE IMMUNIZATION SERIES AS INFANTS IN STUDY V72P12: